TAK-577
PreclinicalBiologic
TakedaTAK-577 is one of 9 biologic programs targeting Von Willebrand disease. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Von Willebrand Disease
#DrugCompanyPhaseTrials
1Advate
TakedaPhase 3
Vonicog Alfa
TakedaPhase 3
Antihemophilic Factor (recombinant)
TakedaPhase 3
VGA039
VVega Therapeutics, Inc
Phase 3
BT200
BBand Therapeutics
Phase 2
Activated Prothrombin Complex Concentrate
RochePreclinical
Recombinant Interferon Alfa 2a
RochePreclinical
Von Willebrand Factor Concentrates
RochePreclinical
TAK-577
TakedaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TAK-577. EMBL-EBI & Wellcome Sanger Institute.
- [4]